The ACTIV-6 trial, published in the New England Journal of Medicine in 2023, examines the effectiveness of inhaled fluticasone furoate in the treatment of non-hospitalized patients with mild to moderate COVID-19. The trial was a decentralized, double-blind, randomized, placebo-controlled study … Read More
